NCT01207440 · BASELINE
Baseline characteristics
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- denoms
- counts
- group Id
- BG000
- value
- 203
- group Id
- BG001
- value
- 64
- group Id
- BG002
- value
- 65
- group Id
- BG003
- value
- 18
- group Id
- BG004
- value
- 48
- group Id
- BG005
- value
- 46
- group Id
- BG006
- value
- 5
- group Id
- BG007
- value
- 449
- units
- Participants
- groups
- description
- CP-CML participants R-I to dasatinib or nilotinib were administered ponatinib 45 mg, tablet, orally, once daily until disease progression or development of intolerance or if they met one or more of the protocol defined criteria for discontinuation (Up to approximately 48 months).
- id
- BG000
- title
- Cohort A: CP-CML R-I
- description
- CP-CML participants who had T315I mutation of breakpoint cluster region-Abelson complex (BCR-ABL) were administered ponatinib 45 mg, tablet, orally, once daily until disease progression or development of intolerance or if they met one or more of the protocol defined criteria for discontinuation (Up to approximately 48 months).
- id
- BG001
- title
- Cohort B: CP-CML With T315I Mutation
- description
- AP-CML R-I to dasatinib or nilotinib were administered ponatinib 45 mg, tablet, orally, once daily until disease progression or development of intolerance or if they met one or more of the protocol defined criteria for discontinuation (Up to approximately 48 months).
- id
- BG002
- title
- Cohort C: AP-CML R-I
- description
- AP-CML participants who had T315I mutation of BCR-ABL were administered ponatinib 45 mg, tablet, orally, once daily until disease progression or development of intolerance or if they met one or more of the protocol defined criteria for discontinuation (Up to approximately 48 months).
- id
- BG003
- title
- Cohort D: AP-CML With T315I Mutation
- description
- BP-CML or Ph+ ALL R-I to dasatinib or nilotinib or Ph+ ALL R-I to dasatinib or nilotinib were administered ponatinib 45 mg, tablet, orally, once daily until disease progression or development of intolerance or if they met one or more of the protocol defined criteria for discontinuation (Up to approximately 48 months).
- id
- BG004
- title
- Cohort E: BP-CML/Ph+ ALL R-I
- description
- BP-CML or Ph+ ALL participants who had T315I mutation of BCR-ABL were administered ponatinib 45 mg, tablet, orally, once daily until disease progression or development of intolerance or if they met one or more of the protocol defined criteria for discontinuation (Up to approximately 48 months).
- id
- BG005
- title
- Cohort F: BP-CML or Ph+ ALL With T315I Mutation
- description
- Participants who were not assigned to any of the cohorts and have no T315I mutation at study entry and were not resistant or intolerant to dasatinib or nilotinib, administered ponatinib 45 mg, tablet, orally, once daily until disease progression or development of intolerance or if they met one or more of the protocol defined criteria for discontinuation (Up to approximately 48 months).
- id
- BG006
- title
- Unassigned to Cohorts A-F
- description
- Total of all reporting groups
- id
- BG007
- title
- Total
- measures
- classes
- categories
- measurements
- group Id
- BG000
- lower Limit
- 22
- upper Limit
- 94
- value
- 61.0
- group Id
- BG001
- lower Limit
- 18
- upper Limit
- 87
- value
- 52.0
- group Id
- BG002
- lower Limit
- 23
- upper Limit
- 82
- value
- 60.0
- group Id
- BG003
- lower Limit
- 24
- upper Limit
- 78
- value
- 54.0
- group Id
- BG004
- lower Limit
- 18
- upper Limit
- 74
- value
- 54.0
- group Id
- BG005
- lower Limit
- 18
- upper Limit
- 80
- value
- 56.0
- group Id
- BG006
- lower Limit
- 51
- upper Limit
- 71
- value
- 63.0
- group Id
- BG007
- lower Limit
- 18
- upper Limit
- 94
- value
- 59.0
- denoms
- counts
- group Id
- BG000
- value
- 203
- group Id
- BG001
- value
- 64
- group Id
- BG002
- value
- 65
- group Id
- BG003
- value
- 18
- group Id
- BG004
- value
- 48
- group Id
- BG005
- value
- 46
- group Id
- BG006
- value
- 5
- group Id
- BG007
- value
- 449
- units
- Participants
- dispersion Type
- FULL_RANGE
- param Type
- MEDIAN
- title
- Age, Continuous
- unit Of Measure
- years
- classes
- categories
- measurements
- group Id
- BG000
- value
- 108
- group Id
- BG001
- value
- 16
- group Id
- BG002
- value
- 40
- group Id
- BG003
- value
- 7
- group Id
- BG004
- value
- 17
- group Id
- BG005
- value
- 20
- group Id
- BG006
- value
- 3
- group Id
- BG007
- value
- 211
- title
- Female
- measurements
- group Id
- BG000
- value
- 95
- group Id
- BG001
- value
- 48
- group Id
- BG002
- value
- 25
- group Id
- BG003
- value
- 11
- group Id
- BG004
- value
- 31
- group Id
- BG005
- value
- 26
- group Id
- BG006
- value
- 2
- group Id
- BG007
- value
- 238
- title
- Male
- denoms
- counts
- group Id
- BG000
- value
- 203
- group Id
- BG001
- value
- 64
- group Id
- BG002
- value
- 65
- group Id
- BG003
- value
- 18
- group Id
- BG004
- value
- 48
- group Id
- BG005
- value
- 46
- group Id
- BG006
- value
- 5
- group Id
- BG007
- value
- 449
- units
- Participants
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Sex: Female, Male
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 13
- group Id
- BG001
- value
- 8
- group Id
- BG002
- value
- 6
- group Id
- BG003
- value
- 1
- group Id
- BG004
- value
- 2
- group Id
- BG005
- value
- 12
- group Id
- BG006
- value
- 0
- group Id
- BG007
- value
- 42
- title
- Hispanic or Latino
- measurements
- group Id
- BG000
- value
- 190
- group Id
- BG001
- value
- 56
- group Id
- BG002
- value
- 59
- group Id
- BG003
- value
- 17
- group Id
- BG004
- value
- 46
- group Id
- BG005
- value
- 34
- group Id
- BG006
- value
- 5
- group Id
- BG007
- value
- 407
- title
- Not Hispanic or Latino
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 0
- group Id
- BG004
- value
- 0
- group Id
- BG005
- value
- 0
- group Id
- BG006
- value
- 0
- group Id
- BG007
- value
- 0
- title
- Unknown or Not Reported
- denoms
- counts
- group Id
- BG000
- value
- 203
- group Id
- BG001
- value
- 64
- group Id
- BG002
- value
- 65
- group Id
- BG003
- value
- 18
- group Id
- BG004
- value
- 48
- group Id
- BG005
- value
- 46
- group Id
- BG006
- value
- 5
- group Id
- BG007
- value
- 449
- units
- Participants
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Ethnicity (NIH/OMB)
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 1
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 1
- group Id
- BG003
- value
- 0
- group Id
- BG004
- value
- 0
- group Id
- BG005
- value
- 0
- group Id
- BG006
- value
- 0
- group Id
- BG007
- value
- 2
- title
- American Indian/Alaska native
- measurements
- group Id
- BG000
- value
- 17
- group Id
- BG001
- value
- 14
- group Id
- BG002
- value
- 8
- group Id
- BG003
- value
- 3
- group Id
- BG004
- value
- 8
- group Id
- BG005
- value
- 7
- group Id
- BG006
- value
- 2
- group Id
- BG007
- value
- 59
- title
- Asian
- measurements
- group Id
- BG000
- value
- 7
- group Id
- BG001
- value
- 4
- group Id
- BG002
- value
- 7
- group Id
- BG003
- value
- 5
- group Id
- BG004
- value
- 1
- group Id
- BG005
- value
- 1
- group Id
- BG006
- value
- 0
- group Id
- BG007
- value
- 25
- title
- Black/African American
- measurements
- group Id
- BG000
- value
- 174
- group Id
- BG001
- value
- 42
- group Id
- BG002
- value
- 47
- group Id
- BG003
- value
- 9
- group Id
- BG004
- value
- 39
- group Id
- BG005
- value
- 38
- group Id
- BG006
- value
- 3
- group Id
- BG007
- value
- 352
- title
- White
- measurements
- group Id
- BG000
- value
- 3
- group Id
- BG001
- value
- 3
- group Id
- BG002
- value
- 2
- group Id
- BG003
- value
- 0
- group Id
- BG004
- value
- 0
- group Id
- BG005
- value
- 0
- group Id
- BG006
- value
- 0
- group Id
- BG007
- value
- 8
- title
- Unknown
- measurements
- group Id
- BG000
- value
- 1
- group Id
- BG001
- value
- 1
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 1
- group Id
- BG004
- value
- 0
- group Id
- BG005
- value
- 0
- group Id
- BG006
- value
- 0
- group Id
- BG007
- value
- 3
- title
- Other
- denoms
- counts
- group Id
- BG000
- value
- 203
- group Id
- BG001
- value
- 64
- group Id
- BG002
- value
- 65
- group Id
- BG003
- value
- 18
- group Id
- BG004
- value
- 48
- group Id
- BG005
- value
- 46
- group Id
- BG006
- value
- 5
- group Id
- BG007
- value
- 449
- units
- Participants
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Race/Ethnicity, Customized
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 139
- group Id
- BG001
- value
- 47
- group Id
- BG002
- value
- 33
- group Id
- BG003
- value
- 12
- group Id
- BG004
- value
- 15
- group Id
- BG005
- value
- 16
- group Id
- BG006
- value
- 5
- group Id
- BG007
- value
- 267
- title
- ECOG=0
- measurements
- group Id
- BG000
- value
- 60
- group Id
- BG001
- value
- 17
- group Id
- BG002
- value
- 25
- group Id
- BG003
- value
- 6
- group Id
- BG004
- value
- 20
- group Id
- BG005
- value
- 19
- group Id
- BG006
- value
- 0
- group Id
- BG007
- value
- 147
- title
- ECOG=1
- measurements
- group Id
- BG000
- value
- 4
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 7
- group Id
- BG003
- value
- 0
- group Id
- BG004
- value
- 12
- group Id
- BG005
- value
- 11
- group Id
- BG006
- value
- 0
- group Id
- BG007
- value
- 34
- title
- ECOG=2
- denoms
- counts
- group Id
- BG000
- value
- 203
- group Id
- BG001
- value
- 64
- group Id
- BG002
- value
- 65
- group Id
- BG003
- value
- 18
- group Id
- BG004
- value
- 47
- group Id
- BG005
- value
- 46
- group Id
- BG006
- value
- 5
- group Id
- BG007
- value
- 448
- units
- Participants
- description
- ECOG-PS measured on-therapy assessed participant's performance status on 5 point scale: 0=Fully active/able to carry on all pre-disease activities without restriction; 1=restricted in physically strenuous activity, ambulatory/able to carry out light or sedentary work; 2=ambulatory (\>50% of waking hrs), capable of all self care, unable to carry out any work activities; 3=capable of only limited self care, confined to bed/chair \>50% of waking hrs; 4=completely disabled, cannot carry on any self care, totally confined to bed/chair; 5=dead.
- param Type
- COUNT_OF_PARTICIPANTS
- population Description
- 1 participant from the cohort F had missing ECOG data.
- title
- Eastern Cooperative Oncology Group (ECOG) Performance Status (PS)
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- lower Limit
- 0.45
- upper Limit
- 27.43
- value
- 7.85
- group Id
- BG001
- lower Limit
- 1.16
- upper Limit
- 19.49
- value
- 4.78
- group Id
- BG002
- lower Limit
- 0.33
- upper Limit
- 28.47
- value
- 7.13
- group Id
- BG003
- lower Limit
- 1.17
- upper Limit
- 15.90
- value
- 6.61
- group Id
- BG004
- lower Limit
- 0.62
- upper Limit
- 27.21
- value
- 3.96
- group Id
- BG005
- lower Limit
- 0.46
- upper Limit
- 14.14
- value
- 1.63
- group Id
- BG006
- lower Limit
- 1.74
- upper Limit
- 18.60
- value
- 4.80
- group Id
- BG007
- lower Limit
- 0.33
- upper Limit
- 28.47
- value
- 6.09
- denoms
- counts
- group Id
- BG000
- value
- 203
- group Id
- BG001
- value
- 64
- group Id
- BG002
- value
- 65
- group Id
- BG003
- value
- 18
- group Id
- BG004
- value
- 48
- group Id
- BG005
- value
- 46
- group Id
- BG006
- value
- 5
- group Id
- BG007
- value
- 449
- units
- Participants
- dispersion Type
- FULL_RANGE
- param Type
- MEDIAN
- title
- Time From Diagnosis to First Dose
- unit Of Measure
- years
- population Description
- The safety population included all participants who received at least 1 dose of ponatinib.
Complete source fields
- denoms
- counts
- group Id
- BG000
- value
- 203
- group Id
- BG001
- value
- 64
- group Id
- BG002
- value
- 65
- group Id
- BG003
- value
- 18
- group Id
- BG004
- value
- 48
- group Id
- BG005
- value
- 46
- group Id
- BG006
- value
- 5
- group Id
- BG007
- value
- 449
- units
- Participants
- groups
- description
- CP-CML participants R-I to dasatinib or nilotinib were administered ponatinib 45 mg, tablet, orally, once daily until disease progression or development of intolerance or if they met one or more of the protocol defined criteria for discontinuation (Up to approximately 48 months).
- id
- BG000
- title
- Cohort A: CP-CML R-I
- description
- CP-CML participants who had T315I mutation of breakpoint cluster region-Abelson complex (BCR-ABL) were administered ponatinib 45 mg, tablet, orally, once daily until disease progression or development of intolerance or if they met one or more of the protocol defined criteria for discontinuation (Up to approximately 48 months).
- id
- BG001
- title
- Cohort B: CP-CML With T315I Mutation
- description
- AP-CML R-I to dasatinib or nilotinib were administered ponatinib 45 mg, tablet, orally, once daily until disease progression or development of intolerance or if they met one or more of the protocol defined criteria for discontinuation (Up to approximately 48 months).
- id
- BG002
- title
- Cohort C: AP-CML R-I
- description
- AP-CML participants who had T315I mutation of BCR-ABL were administered ponatinib 45 mg, tablet, orally, once daily until disease progression or development of intolerance or if they met one or more of the protocol defined criteria for discontinuation (Up to approximately 48 months).
- id
- BG003
- title
- Cohort D: AP-CML With T315I Mutation
- description
- BP-CML or Ph+ ALL R-I to dasatinib or nilotinib or Ph+ ALL R-I to dasatinib or nilotinib were administered ponatinib 45 mg, tablet, orally, once daily until disease progression or development of intolerance or if they met one or more of the protocol defined criteria for discontinuation (Up to approximately 48 months).
- id
- BG004
- title
- Cohort E: BP-CML/Ph+ ALL R-I
- description
- BP-CML or Ph+ ALL participants who had T315I mutation of BCR-ABL were administered ponatinib 45 mg, tablet, orally, once daily until disease progression or development of intolerance or if they met one or more of the protocol defined criteria for discontinuation (Up to approximately 48 months).
- id
- BG005
- title
- Cohort F: BP-CML or Ph+ ALL With T315I Mutation
- description
- Participants who were not assigned to any of the cohorts and have no T315I mutation at study entry and were not resistant or intolerant to dasatinib or nilotinib, administered ponatinib 45 mg, tablet, orally, once daily until disease progression or development of intolerance or if they met one or more of the protocol defined criteria for discontinuation (Up to approximately 48 months).
- id
- BG006
- title
- Unassigned to Cohorts A-F
- description
- Total of all reporting groups
- id
- BG007
- title
- Total
- measures
- classes
- categories
- measurements
- group Id
- BG000
- lower Limit
- 22
- upper Limit
- 94
- value
- 61.0
- group Id
- BG001
- lower Limit
- 18
- upper Limit
- 87
- value
- 52.0
- group Id
- BG002
- lower Limit
- 23
- upper Limit
- 82
- value
- 60.0
- group Id
- BG003
- lower Limit
- 24
- upper Limit
- 78
- value
- 54.0
- group Id
- BG004
- lower Limit
- 18
- upper Limit
- 74
- value
- 54.0
- group Id
- BG005
- lower Limit
- 18
- upper Limit
- 80
- value
- 56.0
- group Id
- BG006
- lower Limit
- 51
- upper Limit
- 71
- value
- 63.0
- group Id
- BG007
- lower Limit
- 18
- upper Limit
- 94
- value
- 59.0
- denoms
- counts
- group Id
- BG000
- value
- 203
- group Id
- BG001
- value
- 64
- group Id
- BG002
- value
- 65
- group Id
- BG003
- value
- 18
- group Id
- BG004
- value
- 48
- group Id
- BG005
- value
- 46
- group Id
- BG006
- value
- 5
- group Id
- BG007
- value
- 449
- units
- Participants
- dispersion Type
- FULL_RANGE
- param Type
- MEDIAN
- title
- Age, Continuous
- unit Of Measure
- years
- classes
- categories
- measurements
- group Id
- BG000
- value
- 108
- group Id
- BG001
- value
- 16
- group Id
- BG002
- value
- 40
- group Id
- BG003
- value
- 7
- group Id
- BG004
- value
- 17
- group Id
- BG005
- value
- 20
- group Id
- BG006
- value
- 3
- group Id
- BG007
- value
- 211
- title
- Female
- measurements
- group Id
- BG000
- value
- 95
- group Id
- BG001
- value
- 48
- group Id
- BG002
- value
- 25
- group Id
- BG003
- value
- 11
- group Id
- BG004
- value
- 31
- group Id
- BG005
- value
- 26
- group Id
- BG006
- value
- 2
- group Id
- BG007
- value
- 238
- title
- Male
- denoms
- counts
- group Id
- BG000
- value
- 203
- group Id
- BG001
- value
- 64
- group Id
- BG002
- value
- 65
- group Id
- BG003
- value
- 18
- group Id
- BG004
- value
- 48
- group Id
- BG005
- value
- 46
- group Id
- BG006
- value
- 5
- group Id
- BG007
- value
- 449
- units
- Participants
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Sex: Female, Male
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 13
- group Id
- BG001
- value
- 8
- group Id
- BG002
- value
- 6
- group Id
- BG003
- value
- 1
- group Id
- BG004
- value
- 2
- group Id
- BG005
- value
- 12
- group Id
- BG006
- value
- 0
- group Id
- BG007
- value
- 42
- title
- Hispanic or Latino
- measurements
- group Id
- BG000
- value
- 190
- group Id
- BG001
- value
- 56
- group Id
- BG002
- value
- 59
- group Id
- BG003
- value
- 17
- group Id
- BG004
- value
- 46
- group Id
- BG005
- value
- 34
- group Id
- BG006
- value
- 5
- group Id
- BG007
- value
- 407
- title
- Not Hispanic or Latino
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 0
- group Id
- BG004
- value
- 0
- group Id
- BG005
- value
- 0
- group Id
- BG006
- value
- 0
- group Id
- BG007
- value
- 0
- title
- Unknown or Not Reported
- denoms
- counts
- group Id
- BG000
- value
- 203
- group Id
- BG001
- value
- 64
- group Id
- BG002
- value
- 65
- group Id
- BG003
- value
- 18
- group Id
- BG004
- value
- 48
- group Id
- BG005
- value
- 46
- group Id
- BG006
- value
- 5
- group Id
- BG007
- value
- 449
- units
- Participants
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Ethnicity (NIH/OMB)
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 1
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 1
- group Id
- BG003
- value
- 0
- group Id
- BG004
- value
- 0
- group Id
- BG005
- value
- 0
- group Id
- BG006
- value
- 0
- group Id
- BG007
- value
- 2
- title
- American Indian/Alaska native
- measurements
- group Id
- BG000
- value
- 17
- group Id
- BG001
- value
- 14
- group Id
- BG002
- value
- 8
- group Id
- BG003
- value
- 3
- group Id
- BG004
- value
- 8
- group Id
- BG005
- value
- 7
- group Id
- BG006
- value
- 2
- group Id
- BG007
- value
- 59
- title
- Asian
- measurements
- group Id
- BG000
- value
- 7
- group Id
- BG001
- value
- 4
- group Id
- BG002
- value
- 7
- group Id
- BG003
- value
- 5
- group Id
- BG004
- value
- 1
- group Id
- BG005
- value
- 1
- group Id
- BG006
- value
- 0
- group Id
- BG007
- value
- 25
- title
- Black/African American
- measurements
- group Id
- BG000
- value
- 174
- group Id
- BG001
- value
- 42
- group Id
- BG002
- value
- 47
- group Id
- BG003
- value
- 9
- group Id
- BG004
- value
- 39
- group Id
- BG005
- value
- 38
- group Id
- BG006
- value
- 3
- group Id
- BG007
- value
- 352
- title
- White
- measurements
- group Id
- BG000
- value
- 3
- group Id
- BG001
- value
- 3
- group Id
- BG002
- value
- 2
- group Id
- BG003
- value
- 0
- group Id
- BG004
- value
- 0
- group Id
- BG005
- value
- 0
- group Id
- BG006
- value
- 0
- group Id
- BG007
- value
- 8
- title
- Unknown
- measurements
- group Id
- BG000
- value
- 1
- group Id
- BG001
- value
- 1
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 1
- group Id
- BG004
- value
- 0
- group Id
- BG005
- value
- 0
- group Id
- BG006
- value
- 0
- group Id
- BG007
- value
- 3
- title
- Other
- denoms
- counts
- group Id
- BG000
- value
- 203
- group Id
- BG001
- value
- 64
- group Id
- BG002
- value
- 65
- group Id
- BG003
- value
- 18
- group Id
- BG004
- value
- 48
- group Id
- BG005
- value
- 46
- group Id
- BG006
- value
- 5
- group Id
- BG007
- value
- 449
- units
- Participants
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Race/Ethnicity, Customized
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 139
- group Id
- BG001
- value
- 47
- group Id
- BG002
- value
- 33
- group Id
- BG003
- value
- 12
- group Id
- BG004
- value
- 15
- group Id
- BG005
- value
- 16
- group Id
- BG006
- value
- 5
- group Id
- BG007
- value
- 267
- title
- ECOG=0
- measurements
- group Id
- BG000
- value
- 60
- group Id
- BG001
- value
- 17
- group Id
- BG002
- value
- 25
- group Id
- BG003
- value
- 6
- group Id
- BG004
- value
- 20
- group Id
- BG005
- value
- 19
- group Id
- BG006
- value
- 0
- group Id
- BG007
- value
- 147
- title
- ECOG=1
- measurements
- group Id
- BG000
- value
- 4
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 7
- group Id
- BG003
- value
- 0
- group Id
- BG004
- value
- 12
- group Id
- BG005
- value
- 11
- group Id
- BG006
- value
- 0
- group Id
- BG007
- value
- 34
- title
- ECOG=2
- denoms
- counts
- group Id
- BG000
- value
- 203
- group Id
- BG001
- value
- 64
- group Id
- BG002
- value
- 65
- group Id
- BG003
- value
- 18
- group Id
- BG004
- value
- 47
- group Id
- BG005
- value
- 46
- group Id
- BG006
- value
- 5
- group Id
- BG007
- value
- 448
- units
- Participants
- description
- ECOG-PS measured on-therapy assessed participant's performance status on 5 point scale: 0=Fully active/able to carry on all pre-disease activities without restriction; 1=restricted in physically strenuous activity, ambulatory/able to carry out light or sedentary work; 2=ambulatory (\>50% of waking hrs), capable of all self care, unable to carry out any work activities; 3=capable of only limited self care, confined to bed/chair \>50% of waking hrs; 4=completely disabled, cannot carry on any self care, totally confined to bed/chair; 5=dead.
- param Type
- COUNT_OF_PARTICIPANTS
- population Description
- 1 participant from the cohort F had missing ECOG data.
- title
- Eastern Cooperative Oncology Group (ECOG) Performance Status (PS)
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- lower Limit
- 0.45
- upper Limit
- 27.43
- value
- 7.85
- group Id
- BG001
- lower Limit
- 1.16
- upper Limit
- 19.49
- value
- 4.78
- group Id
- BG002
- lower Limit
- 0.33
- upper Limit
- 28.47
- value
- 7.13
- group Id
- BG003
- lower Limit
- 1.17
- upper Limit
- 15.90
- value
- 6.61
- group Id
- BG004
- lower Limit
- 0.62
- upper Limit
- 27.21
- value
- 3.96
- group Id
- BG005
- lower Limit
- 0.46
- upper Limit
- 14.14
- value
- 1.63
- group Id
- BG006
- lower Limit
- 1.74
- upper Limit
- 18.60
- value
- 4.80
- group Id
- BG007
- lower Limit
- 0.33
- upper Limit
- 28.47
- value
- 6.09
- denoms
- counts
- group Id
- BG000
- value
- 203
- group Id
- BG001
- value
- 64
- group Id
- BG002
- value
- 65
- group Id
- BG003
- value
- 18
- group Id
- BG004
- value
- 48
- group Id
- BG005
- value
- 46
- group Id
- BG006
- value
- 5
- group Id
- BG007
- value
- 449
- units
- Participants
- dispersion Type
- FULL_RANGE
- param Type
- MEDIAN
- title
- Time From Diagnosis to First Dose
- unit Of Measure
- years
- population Description
- The safety population included all participants who received at least 1 dose of ponatinib.
Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0
Preserved source evidence · Not medical advice
Triangle